Activities of Daily Living
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Aged
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Aged, 80 and over
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Alzheimer Disease
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Amyloid beta-Peptides
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Antibodies, Monoclonal, Humanized
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Apolipoproteins E
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Biomarkers
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Cognition
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Cognition Disorders
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Double-Blind Method
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Female
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Humans
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Intention to Treat Analysis
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Male
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
National Institute on Aging (U.S.)
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Neuropsychological Tests
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Practice Guidelines as Topic
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
Severity of Illness Index
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
tau Proteins
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Treatment Failure
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
United States
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H.,
“Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”,
Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.